Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Search by expertise, name or affiliation
Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis
Krisstina Gowin, Ruben Mesa
Hematology/Oncology
Research output
:
Contribution to journal
›
Review article
›
peer-review
9
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Janus Kinase 2
100%
Philadelphia Chromosome
91%
Primary Myelofibrosis
89%
Janus Kinase Inhibitors
59%
INCB018424
44%
Investigational Therapies
35%
Splenomegaly
31%
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
28%
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
27%
Fedratinib
27%
pomalidomide
23%
Neoplasms
22%
Fibrosis
21%
Phase II Clinical Trials
17%
Immunomodulation
16%
Survival
15%
Expert Testimony
14%
Allografts
12%
Therapeutics
11%
PubMed
11%
Bone Marrow
10%
Pharmaceutical Preparations
5%